Microvast Holdings announces departure of chief financial officer
On Friday, Stifel analysts adjusted their financial outlook for Abeona Therapeutics (NASDAQ:ABEO), reducing the price target to $20.00 from the previous $21.00. Despite this change, the firm has upheld its Buy rating on the company’s stock. The modification comes in light of recent developments that are expected to impact the company’s revenue in the second half of 2025. According to InvestingPro data, analyst targets for ABEO range from $11 to $27.50, with the stock currently trading at $5.73. Want deeper insights? InvestingPro offers exclusive access to comprehensive analyst coverage and Fair Value estimates for over 1,400 US stocks.
The first Zevaskyn Qualified Treatment Center (QTC) has been activated, with the inaugural patient treatment scheduled for August 2025. This progress is seen as a positive indicator for Abeona Therapeutics. Furthermore, approximately 30 patients and caregivers have enrolled in the Abeona Assist patient services program, which is anticipated to contribute to clearer revenue projections for the latter half of 2025 and align with the company’s full-year guidance of treating 10-14 patients.
In addition to the growth in patient and physician interest, there has been progress on the reimbursement front. Abeona’s management has successfully negotiated value-based agreements with several commercial payer groups, which collectively provide coverage for around 100 million individuals. Discussions are ongoing to further expand Zevaskyn’s accessibility with additional commercial and government payers.
The financial position of Abeona Therapeutics has been strengthened by the sale of a priority review voucher (PRV), resulting in $152 million in net proceeds. This capital infusion equates to over $2 per share on a fully-diluted basis, ensuring the company has the necessary funds to meet its commercial and manufacturing objectives, as well as to advance the development of its earlier-stage pipeline. InvestingPro analysis reveals the company holds more cash than debt and maintains a healthy current ratio of 6.08, though it’s currently burning through cash rapidly. Discover more financial health metrics and exclusive ProTips by visiting the comprehensive Pro Research Report for ABEO.
Stifel’s revised price target reflects adjustments in share count and a slight increase in projected selling, general, and administrative (SG&A) expenses for the fiscal year 2025 and beyond.
In other recent news, Abeona Therapeutics Inc. reported its first-quarter 2025 earnings, revealing a smaller-than-expected loss per share. The company’s earnings per share (EPS) stood at -$0.24, surpassing the forecasted -$0.37. Despite reporting no revenue for the quarter, Abeona demonstrated financial improvement by reducing its net loss to $12 million from $31.6 million in the same period the previous year. The FDA’s recent approval of Abeona’s new therapy, ZivaSkin, marks a significant milestone and positions the company as a leader in autologous cell-based gene therapy. The approval is expected to bolster future revenue growth. Additionally, Abeona plans to sell a Priority Review Voucher (PRV), which is anticipated to generate $152 million in proceeds, providing financial stability for the company. Analysts have noted Abeona’s strategic focus and effective cost management, which contributed to the positive earnings surprise. These developments reflect the company’s operational resilience and strategic execution.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.